<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/256533-composition-containing-statins-and-omega-3-fatty-acids by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:26:57 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 256533:&quot;COMPOSITION CONTAINING STATINS AND OMEGA-3 FATTY ACIDS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;COMPOSITION CONTAINING STATINS AND OMEGA-3 FATTY ACIDS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a synergistic effect and is useful in the treatment of disease forms due to insulin resistance and in cardiovascular diseases.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Composition containing statins and omega-3 fatty acids<br>
The present invention relates to a combination of active ingredients<br>
and to compositions containing this combination in medical use and in<br>
the preparation of medicaments useful for the treatment of type 2 dia-<br>
betes and cardiovascular diseases.<br>
Diabetes is a widespread disease throughout the world and is associ-<br>
ated with major clinical complications involving the microvascular dis-<br>
trict, such as diabetic retinopathy, diabetic neuropathy and nephropa-<br>
thy, and the macrovascular district, such as atherosclerosis, peripheral<br>
vasculopathies, myocardial infarct and stroke.<br>
Insulin resistance, which characterises type 2 diabetes and its micro-<br>
and macrovascular complications is also involved in syndrome X, poly-<br>
cystic ovary syndrome, obesity, hypertension, hyperlipidaemias and<br>
hypercholesterolaemias (J. Am. Osteopath. Assoc, 2000 Oct.;<br>
100(10):621-34; Jama, 2002 Nov., 27;288(20):2579-88).<br>
It is known that hyperlipidaemias, hypercholesterolaemias and hyper-<br>
tension play a decisive role in the onset of coronary heart disease<br>
(CHD).<br>
It is also known that an increase in glycosylation of proteins is in-<br>
volved in the above-mentioned complications of diabetes (Diabetologia<br>
2001 Feb; 44(2):129-46).<br>
Said complications constitute a serious threat to the life and well-being<br>
of the individual.<br>
Various clinical forms of diabetic disease are known, the most common<br>
being type 2 and type 1 diabetes. Type 2 diabetes is characterised by<br>
reduced sensitivity to the action of insulin (insulin resistance) and<br>
gives rise to an increase in insulin levels in the body in an attempt to<br>
compensate for this deficiency and to a consequent increase in glucose<br><br>
levels. Numerous reports have confirmed the involvement of insulin<br>
resistance in many disease conditions in addition to type 2 diabetes<br>
itself, such as dyslipidaemia, obesity, arterial hypertension and certain<br>
macrovascular and microvascular manifestations characteristic of dia-<br>
betic disease itself. The combination of insulin resistance and obesity,<br>
hypertension and dyslipidaemia is known as Syndrome X.<br>
Drugs used for many years such as the biguanides and sulphonylurea<br>
drugs are available on the market for the treatment of type 2 diabetes.<br>
Many of these, such as, for example, methformin, present gastrointes-<br>
tinal disorders, danger of acidosis in conditions of renal, cardiac, he-<br>
patic, pulmonary insufficiency, etc., as side effects. The sulphonylureas<br>
have episodes of hypoglycaemia as their possible side effects. Drugs<br>
recently introduced onto the market are the thiazolidinediones, whose<br>
side effects such as liver toxicity, increased LDL cholesterol, weight<br>
gain and oedema have given cause for concern.<br>
Hyperlipidaemia is a serious aspect of diabetic disease, constituting,<br>
together with the hypertension which is often present, a risk factor for<br>
atherosclerosis and for cardiovascular disease which is the primary<br>
cause of death in diabetes.<br>
Cardiovascular disease is recognised as the primary cause of death in<br>
the industrialised countries with a high standard of living.<br>
The social cost is enormous, both in terms of disability and invalidity<br>
of subjects suffering from it, and in terms of the actual cost of health<br>
facilities and insurance.<br>
Dyslipidaemia is often associated, also as a consequence, with diabe-<br>
tes.<br>
In WO 02/43659 a combination of statin, docosahexanoic acid, vitamins<br>
E, C B6 and B12, folic acid and calcium is described to reduce the risk<br>
factors for cardiovascular disease, such as hypercholesterolaemia and<br><br>
hypertension. In this document there is never any mention of insulin<br>
resistance.<br>
Ever increasing attention is being devoted to the so-called risk factors<br>
recognised as underlying these diseases, and there is still a perceived<br>
need for a medicament capable of acting on the various sources of this<br>
pathological picture, without, at the same time, being associated with<br>
severe side effects, which, as in the case of certain antidiabetic drugs,<br>
may even make it necessary to discontinue the therapy.<br>
Summary of the invention<br>
It has now surprisingly been found that a certain combination of sub-<br>
stances, known for their specific pharmacological actions, is particu-<br>
larly indicated for the treatment of insulin resistance, and of the<br>
pathological aspects related to it, as well as of cardiovascular diseases.<br>
The combination according to the invention comprises essentially at<br>
least one omega-3 fatty acid, optionally esterified or salified, at least<br>
one statin, Coenzyme Q10, resveratrol, at least one policosanol,<br>
pantethine, selenium and zinc.<br>
The unique combination according to the present invention exerts a<br>
surprising effect on insulin resistance, which is not predictable on the<br>
basis of our knowledge of the individual components thereof, and, in<br>
any event, their combination leads to an unexpected synergistic effect.<br>
The advantage of having such a combination is therefore evident to<br>
experts in the field. It is possible, in fact, to treat insulin resistance,<br>
and the pathological forms related to it, particularly as regards the<br>
implications of abnormal lipid status, and, at the same time, the com-<br>
plications or risks affecting the cardiocirculatory system.<br><br>
The combination according to the present invention can also be used<br>
for the treatment of cardiovascular diseases, without there necessarily-<br>
being any need to treat insulin resistance.<br>
Therefore, one object of the present invention is a combination com-<br>
prising at least one omega-3 fatty acid, optionally esterified or salified,<br>
at least one statin, Coenzyme Q10, resveratrol, at least one polico-<br>
sanol, pantethine, selenium, and zinc.<br>
The combination according to the invention can also comprise other<br>
useful elements, without this substantially impairing the activity.<br>
Another object of the present invention is a pharmaceutical composi-<br>
tion containing the above-mentioned combination, optionally in a mix-<br>
ture with one or more pharmaceutically acceptable vehicles or excipi-<br>
ents.<br>
The combination according to the present invention can also be formu-<br>
lated as a food supplement, which constitutes a further object of the<br>
invention.<br>
Other objects of the present invention are various uses of the above-<br>
mentioned combination as a medicament, in particular for the prepa-<br>
ration of a medicament for the treatment of insulin resistance and type<br>
2 diabetes, with antilipaemic action and a protective action on the car-<br>
diovascular system.<br>
In particular, the present invention provides for the use of the above-<br>
mentioned combination for the preparation of a medicament useful for<br>
the treatment of diseases involving insulin resistance, such as type 2<br>
diabetes, Syndrome X, polycystic ovary syndrome, obesity, hyperten-<br>
sion, hperlipidaemias and hypercholesterolaemias.<br>
The medicament according to the invention can be used to treat the<br>
individual disease states or to exert a preventive or protective action<br><br>
against them, or to treat a complex pathological picture that includes<br>
one or more of the therapeutic aspects seen above. For example, a me-<br>
dicament with a combined action for the treatment of type 2 diabetes<br>
and insulin resistance and an antilipaemic and protective action on the<br>
cardiovascular system, particularly in certain severe forms of type 2<br>
diabetes associated with obesity.<br>
Detailed description of the invention<br>
The combination according to the present invention consists essen-<br>
tially of active ingredients which are known in the medical field and<br>
already used in clinical practice. Therefore, they are very easy to pro-<br>
cure, inasmuch as they are products which have been on the market<br>
for some time and are of a grade suitable for human or animal admini-<br>
stration.<br>
The statins are a known class of drugs used for lowering cholesterol<br>
levels. Statins are available on the market or can be prepared accord-<br>
ing to known methods described in the literature.<br>
Any statin is suitable for the purposes of the present invention. Exam-<br>
ples of statins are simvastatin, lovastatin, fluvastatin, pravastatin,<br>
atorvastatin, cerivastatin and rosuvastatin. Among these, the one pre-<br>
ferred is simvastatin.<br>
According to the present invention, it is also possible to combine a<br>
number of statins, depending on their pharmacological characteristics<br>
and on the basis of the common knowledge of experts in the field.<br>
The omega-3 fatty acids are known for their triglyceride-lowering ef-<br>
fects and for their effects in raising the levels of high-density lipopro-<br>
teins (HDL). These fatty acids can be obtained by synthesis or, pref-<br>
erably, from fish oil. Inthat case, it is possible to use various mixtures<br>
of omega-3 fatty acids depending on their characteristics. Preferably,<br>
the omega-3 fatty acids are the long-chain ones (from 20 to 22 carbon<br><br>
atoms). The ones most preferred are 5,8,11,14,17-eicosapentanoic acid<br>
(EPA) and cis 0,13,16,19-docosahexanoic acid (DHA). In a preferred<br>
embodiment of the invention, the omega-5 fatty acid is cis<br>
4,7,10,13,16,19-docosahexanoic acid (DHA), most preferably in a ratio<br>
of 1:1. These omega-3 fatty acids can optionally be esterified or salified<br>
to pharmaceutically acceptable derivatives, with alcohols or bases, re-<br>
spectively. The omega-3 fatty acids, or their esters or salts, alone or in<br>
mixtures thereof, can be procured on the market, or can be prepared by<br>
known methods. The mixtures can be specifically formulated for the<br>
combination according to the invention.<br>
Coenzyme Q10 is now so well known in its human use that it requires<br>
no particular explanation and the substance is available on the mar-<br>
ket. Experts in the field can refer to the patent documents filed by the<br>
present applicant, where this substance is amply described.<br>
Similar considerations also apply to resveratrol.<br>
The policosanols are long-chain aliphatic alcohols. Examples of polico-<br>
sanols are triacontanol, hexacosanol, hexacontanol, ecocontanol, tetra-<br>
cosanol, dotriacontanol, and tetracontanol. The policosonal can be pre-<br>
sent as such or in the form of an extract from natural products that<br>
contain it, e.g. wheat or rice germs, the waxy cuticle of sugar cane, or<br>
Ginkgo biloba leaves. See, for example, WO 99/06039.<br>
Pantethine is used on compositions for hair cosmetics and also in com-<br>
positions for the treatment of dyslipidaemias, as described, for exam-<br>
ple, in WO 2004/041257. It is therefore a well-known compound avail-<br>
able to the expert in the field.<br>
Selenium and zinc are commonly used in food supplements, as de-<br>
scribed in several patents, e.g. EP 0 797 993 and US 6.602.512.<br><br>
As already mentioned, the individual components have long been used<br>
in human subjects, and therefore their pharmaco-toxicological profiles<br>
are known.<br>
This implies that, apart from the consideration of the synergistic effect<br>
demonstrated here below, the dosages and ratios of the individual<br>
components can be determined by the expert in the field with normal<br>
preclinical and clinical trials, or with the usual considerations regard-<br>
ing the formulation of a dietetic product.<br>
The amounts of the individual compounds advised for the preparation<br>
of a pharmaceutical composition for human use are the following.<br>
Omega-3 fatty acid: from 500 mg to 2 g/day, preferably 1 g/day;<br>
Simvastatin; from 10 mg to 40 mg/day, preferably 10 mg/day;<br>
Coenzyme Q10: from 5 mg to 50 mg/day, preferably 10 mg/day;<br>
Resveratrol: from 1 mg to 5 mg/day, preferably 2.5 mg/day;<br>
Policosanols: hexacosanol: from 5 mg to 15 mg/day, preferably 10<br>
mg/day;<br>
Pantethine: from 10 mg to 30 mg/day, preferably 20 mg/day;<br>
Selenium: from 25 ug to 75 ug/day, preferably 50 ug/day;<br>
Zinc: from 5 mg to 15 mg/day, preferablylO mg/day.<br>
The pharmaceutical composition can have a unitary form, in which the<br>
active ingredients are present in a single pharmaceutical form (tablet,<br>
sachet, capsule, vial) or the active ingredients can be administered in a<br>
coordinated sequential manner. In the latter case, the pharmaceutical<br>
composition can be formulated, supplying the components in separate<br><br>
containers, accompanied by instructions for their sequential admini-<br>
stration.<br>
The compositions covered by the present invention are entirely conven-<br>
tional and are obtained with methods that are common practice in the<br>
pharmaceutical industry. According to the administration route opted<br>
for, the compositions will be in solid or liquid form, suitable for oral,<br>
parenteral or intravenous administration. The compositions according<br>
to the present invention contain, along with the active ingredient, at<br>
least one pharmaceutically acceptable vehicle or excipient. Particularly<br>
useful may be formulation adjuvants such as, for example, solubilising<br>
agents, dispersing agents, suspension agents and emulsifying agents.<br>
A general reference work is Remington's Pharmaceutical Sciences<br>
Handbook, latest edition.<br>
The following examples further illustrate the invention.<br>
Example 1<br>
Antidiabetic and serum lipid-lowering activity in db/db mice<br>
Mutations in laboratory animals have made it possible to develop<br>
models that present non-insulin-dependent diabetes associated with<br>
obesity, hyperlipidaemia and insulin resistance and that enable us to<br>
test the efficacy of new antidiabetic compounds (Reed and Scribner,<br>
Diabetes, obesity and metabolism 1: 75 - 86, 1999).<br>
A much used genetically diabetic mouse model is the C57BL/KsJ db/db<br>
mouse.<br>
The genetic basis of this model is a defect in the leptin receptor gene<br>
which gives rise to leptin resistance and leads to hyperphagia, obesity,<br>
hyperinsulinaemia and insulin resistance, with subsequent symptoms<br>
of insufficient insulin secretion and hyperglycaemia (Kodama et al.,<br>
Diabetologia 37: 739 - 744, 1994; Chen et al, Cell 84: 491 - 495, 1996).<br><br>
Since hyperglycaemia is accompanied by obesity and insulin resis-<br>
tance, the db/db mouse has characteristics that are close to those of<br>
type 2 diabetes in man and is useful for assaying insulin-sensitising<br>
compounds.<br>
The C57BL/KsJ db/db mice used in the experiments were supplied by<br>
Jackson Lab (via Ch. River). After 10 days of acclimatisation in stan-<br>
dard conditions (22 ± 2°C; 55 ± 15% humidity; 15-20 air changes/hour;<br>
12 hour light-darkness cycle with light from 7 a.m. to 7 p.m.) on a<br>
standard 4 RF21 diet (Mucedola), blood samples were taken in post-<br>
absorption conditions (fasting from 8.30 a.m. to 4.30 p.m.) from the<br>
caudal vein with the aid of a Jelco 22G catheter (Johnson and John-<br>
son). Glucose, insulin, triglyceride, cholesterol, free fatty acid and urea<br>
levels were checked in the plasma to ensure well-matched distribution<br>
of the mice in the treatment groups.<br>
At the start of treatment, the body weight of the animals was checked<br>
and monitoring of the animals' consumption of water and feed was<br>
scheduled.<br>
The mice were divided into groups and treated orally twice daily with:<br>
Omega-3 fatty acid (EPA +DHA 1:1) 200 mg/kg;<br>
Simvastatin 100 mg/kg;<br>
Omega-3 fatty acid (200 mg/kg) + simvastatin (100 mg/kg);<br>
Omega-3 fatty acid (200 mg/kg) + simvastatin (100 mg/kg); Coenzyme<br>
Q10 (50 mg/kg) + resveratrol (5 mg/kg) + policosanols (hexacosanol 25<br>
mg/kg) + pantethine (100 mg/kg + selenium (0.5 µg/kg) + zinc (2.5<br>
mg/kg).<br><br>
In the course of the experiment, serum glucose levels, glucose toler-<br>
ance (OGTT), a number of lipid status variables and weight gain were<br>
monitored.<br>
The combination according to the invention was capable of lowering<br>
serum glucose levels in the feeding condition (Table 1); in the post-<br>
absorption condition (Table 2); and in the fasting condition (Table 3);<br>
and capable of improving glucose tolerance (Table 4), and of reducing<br>
the levels of fructosamine, an indicator of protein glycosylation (Table<br>
5) which, as mentioned above, plays an important role in the develop-<br>
ment of the micro- and macrovascular complications of diabetes.<br>
The combination according to the invention also shows good ability to<br>
reduce serum triglyceride levels (Table 6) and to increase HDL-<br>
cholesterol levels (Table 7).<br>
An increase in HDL-cholesterol values constitutes an indicator of a<br>
reduced risk of atherosclerosis and of cardiovascular complications<br>
such as atherosclerosis and infarct.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
The results reported above clearly demonstrate the unexpected syner-<br>
gism of the combination according to the present invention, contrary to<br>
what was expected on the basis of the individual components, or even<br>
of the combination of simvastatin and omega-3 fatty acids.<br><br>
WE CLAIM:<br>
1.	Pharmaceutical composition comprising:<br>
a.	omega-3 fatty acid: from 500 mg to 2 g/day;<br>
b.	simvastatin: from 10 mg to 40 mg/day;<br>
c.	Coenzyme Q10: from 5 mg to 50 mg/day;<br>
d.	resveratrol: from 1 mg to 5 mg/day;<br>
e.	policosanols: hexacosanol: from 5 mg to 15 mg/day;<br>
f.	pantethine: from 10 mg to 30 mg/day;<br>
g.	selenium: from 25 µg to 75 µg/day;<br>
h. zinc: from 5 mg to 15 mg/day;<br>
optionally in a mixture with at least one pharmaceutically acceptable vehicle or excipient, such<br>
as herein described.<br>
2.	Composition as claimed in claim 1, wherein the omega-3 fatty acid is selected from cis<br>
5,8,11,14,17-eicosapentanoic acid (EPA) and cis 4,7,10,13,16,19-docosahexanoic acid (DHA), one of<br>
their esters or pharmaceutically acceptable salts, wherein EPA and DHA are in a ratio of 1:1.<br>
3.	Composition as claimed in claim 1 or claim 2, suitable for the administration in unitary form, or<br>
in coordinated, sequential form.<br>
 4. Composition as claimed in any one of claims 1 to 3, in the form of a food supplement for<br>
human or animal.<br>
5. Composition as claimed in any one of claims 1 to 3, which is capable of being used as a<br>
medicament.<br>
6. Composition as claimed in any one of claims 1 to 3, which is capable of being used for the<br>
preparation of a medicament for the treatment of type 2 diabetes and insulin resistance.<br><br>
7.	Composition as claimed in claim 6, which is capable of being used for the preparation of a<br>
medicament with antilipaemic action.<br>
8.	Composition as claimed in claim 6, which is capable of being used for the preparation of a<br>
medicament with protective action on the cardiovascular system.<br>
9.	Composition as claimed in claim 6, which is capable of being used for the preparation of a<br>
medicament useful for the treatment of diseases involving insulin resistance.<br>
10.	Composition as claimed in claim 9, wherein the said disease is selected from type 2 diabetes<br>
and its complications, syndrome X, polycystic ovary syndrome, obesity, hypertension,<br>
hyperlipidaemias and hypercholesterolaemias.<br>
11.	Composition as claimed in claim 6, which is capable of being used for the preparation of<br>
medicament with a combined action for the treatment of type 2 diabetes and insulin resistance, and<br>
antilipaemic and protective on the cardiovascular system.<br><br><br>
(54) Title: COMPOSITION CONTAINING STATINS AND OMEGA-3 FATTY ACIDS<br>
(57) Abstract: A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one<br>
statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a<br>
synergistic effect and is useful in the treatment of disease forms due to insulin resistance and in cardiovascular diseases.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAzODAta29sbnAtMjAwNy1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">00380-kolnp-2007-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAzODAta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZS5wZGY=" target="_blank" style="word-wrap:break-word;">00380-kolnp-2007-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA2IGFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2006 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWNvcnJlc3BvbmRlbmNlIG90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWRlc2NyaXB0aW9uIGNvbXBsZXRlLnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWZvcm0xLnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-form1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWZvcm0zLnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-form3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWZvcm01LnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-form5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWcucC5hLnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-g.p.a.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWludGVybmF0aW5hbCBwdWJsaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-internatinal publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LWludGVybmF0aW5hbCBzZWFyY2ggYXV0aG9yaXR5IHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-internatinal search authority report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM4MC1rb2xucC0yMDA3LXBjdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">0380-kolnp-2007-pct form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctQU1BTkRFRCBDTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctQVNTSUdOTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctQ09SUkVTUE9OREVOQ0UgMS4yLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-CORRESPONDENCE 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctQ09SUkVTUE9OREVOQ0UtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-CORRESPONDENCE-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctREVTQ1JJUFRJT04gKENPTVBMRVRFKS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-DESCRIPTION (COMPLETE)-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRVhBTUlOQVRJT04gUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSAxLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSAxOCAxLjEucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 18 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLWtvbG5wLTIwMDctZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">380-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSAzIDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 3 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSAzLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSA1IDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 5 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctRk9STSA1LTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-FORM 5-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1BBLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1GT1JNIDEucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1GT1JNIDIucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctR1JBTlRFRC1TUEVDSUZJQ0FUSU9OLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctSU5URVJOQVRJT05BTCBQVUJMSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-INTERNATIONAL PUBLICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctSU5URVJOQVRJT05BTCBTRUFSQ0ggUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-INTERNATIONAL SEARCH REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctT1RIRVJTLnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctUEVUSVRJT04gVU5ERVIgUlVMRSAxMzcucGRm" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzgwLUtPTE5QLTIwMDctUkVQTFkgVE8gRVhBTUlOQVRJT04gUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">380-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="256532-ultraviolet-light-uv-absorbing-compounds-and-compositions-containing-uv-absorbing-compounds.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="256534-insulating-double-and-triple-glazing-unit-for-an-opening-leaf-of-a-refrigerated-enclosure-and-the-opening-leaf-and-the-refrigerated-enclosure.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>256533</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>380/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>27/2013</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>05-Jul-2013</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>28-Jun-2013</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>02-Feb-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>VIALE SHAKESPEARE, 47, I-00144 ROME</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CAVAZZA, CLAUDIO</td>
											<td>C/O. SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. VIA PONTINA, KM.30,400, I-00040 POMEZIA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/366,A61K 31/045 ,A61K 31/05</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/IT2005/000414</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-07-19</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>RM2004A000395</td>
									<td>2004-08-03</td>
								    <td>Italy</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/256533-composition-containing-statins-and-omega-3-fatty-acids by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:26:58 GMT -->
</html>
